CareDx Expects Third Quarter 2024 Revenue Of $82M-$83M, Up Approximately 23% YoY, Versus Consensus Of $79.53M

Benzinga · 10/15 10:04
  • Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year.
  • Testing services revenue is expected to be in the range of $60 million to $61 million, an increase of approximately 26% year-over-year. This includes approximately $1.2 million in revenue for tests performed in prior quarters.
  • Patient and Digital Solutions revenue is expected to be approximately $11.9 million, and Products is expected to be approximately $10.2 million, up 20% and 7% year-over-year, respectively.
  • Ended the quarter with cash, cash equivalents, and marketable securities of approximately $240 million with no debt.